(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are FINATIS, CNOVA, and CELYAD ONCOLOGY.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| FINATIS (FNTS.PA) | 9.45 | 18.12% | 2023-03-20 11:49:51 |
| CNOVA (CNV.PA) | 4.71 | 13.49% | 2023-03-20 11:46:29 |
| CELYAD ONCOLOGY (CYAD.BR) | 0.84 | 10.76% | 2023-03-20 08:08:27 |
| SATS (SATS.OL) | 6.83 | 8.41% | 2023-03-20 11:33:50 |
| MAJOREL GROUP LUX (MAJ.AS) | 19.14 | 6.22% | 2023-03-20 11:03:36 |
| OSE IMMUNO (OSE.PA) | 5.20 | 5.68% | 2023-03-20 11:01:10 |
| ITERA (ITERA.OL) | 12.60 | 4.56% | 2023-03-20 11:30:44 |
| ACTEOS (EOS.PA) | 1.73 | 4.55% | 2023-03-20 08:37:27 |
| ONWARD MEDICAL (ONWD.BR) | 4.60 | 4.55% | 2023-03-20 11:16:32 |
| OKEA (OKEA.OL) | 27.85 | 4.5% | 2023-03-20 11:32:25 |
The three biggest losers today are NYRSTAR, GROUPE JAJ, and BALYO.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| NYRSTAR (NYR.BR) | 0.12 | -13.21% | 2023-03-20 11:16:24 |
| GROUPE JAJ (GJAJ.PA) | 1.40 | -11.95% | 2023-03-20 11:51:12 |
| BALYO (BALYO.PA) | 0.67 | -11.57% | 2023-03-20 11:45:09 |
| PIERRE VAC BSA ACT (VACBS.PA) | 0.22 | -10% | 2023-03-20 08:02:16 |
| XILAM ANIMATION (XIL.PA) | 24.00 | -8.57% | 2023-03-20 11:06:58 |
| GENOMIC VISION (GV.PA) | 0.02 | -8.18% | 2023-03-20 11:50:48 |
| ADOCIA (ADOC.PA) | 2.93 | -7.86% | 2023-03-20 11:37:13 |
| KAHOOT! (KAHOT.OL) | 21.44 | -7.55% | 2023-03-20 11:30:51 |
| ERYTECH PHARMA (ERYP.PA) | 0.72 | -7.01% | 2023-03-20 11:48:20 |
| FAURECIA (EO.PA) | 17.52 | -6.73% | 2023-03-20 11:49:16 |
Winners today
1. FINATIS (FNTS.PA)
18.12% Price Change
Finatis Société Anonyme engages in food distribution activities in France and Latin America. It operates monoprix, franprix, casino supermarkets, petit casinos, casino shops, spars, vivals, géant hypermarkets, etc. The company also distributes sports equipment under the Go Sport brand; and invests in real estate properties, as well as manages a portfolio of private equity investments. As of December 31, 2019, it operated a portfolio of 11,172 stores. The company is based in Paris, France. Finatis Société Anonyme is a subsidiary of Euris SAS.
CAC 40 ended the session with FINATIS rising 18.12% to €9.45 on Monday, following the last session’s downward trend. CAC 40 rose 1.27% to €7,013.14, following the last session’s downward trend on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, FINATIS has a trailing twelve months EPS of €-32.99.
Volume
Today’s last reported volume for FINATIS is 948 which is 273.22% above its average volume of 254.
More news about FINATIS.
2. CNOVA (CNV.PA)
13.49% Price Change
Cnova N.V. operates as an e-commerce company in France and Western Europe. The company offers home appliances, consumer electronics, computers, home furnishings, and leisure and personal goods through its cdiscount.com website. It also operates Cdiscount Voyages, a travel platform; Cdiscount Billetterie, a ticketing platform; Cdiscount Energie for home energy; Cdiscount Mobile for cell phone plans; Cdiscount Advertising, a digital marketing solution; Octopia for turnkey marketplace solutions to retailers and e-merchants; and C-Logistics and C Chez Vous for transportation and logistics services. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Cnova N.V. is a subsidiary of Casino, Guichard-Perrachon S.A.
CAC 40 ended the session with CNOVA rising 13.49% to €4.71 on Monday, following the last session’s downward trend. CAC 40 rose 1.27% to €7,013.14, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, CNOVA has a trailing twelve months EPS of €-0.31.
Volatility
CNOVA’s last week, last month’s, and last quarter’s current intraday variation average was 4.83%, 3.17%, and 4.07%.
CNOVA’s highest amplitude of average volatility was 9.44% (last week), 5.75% (last month), and 4.07% (last quarter).
Volume
Today’s last reported volume for CNOVA is 923 which is 34.25% below its average volume of 1404.
Revenue Growth
Year-on-year quarterly revenue growth declined by 29.2%, now sitting on 1.7B for the twelve trailing months.
Yearly Top and Bottom Value
CNOVA’s stock is valued at €4.71 at 21:40 EST, way under its 52-week high of €5.92 and way above its 52-week low of €2.70.
More news about CNOVA.
3. CELYAD ONCOLOGY (CYAD.BR)
10.76% Price Change
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
BEL 20 ended the session with CELYAD ONCOLOGY rising 10.76% to €0.84 on Monday while BEL 20 rose 0.78% to €3,630.99.
Earnings Per Share
As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.234.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CELYAD ONCOLOGY’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for CELYAD ONCOLOGY is 34108 which is 73.1% below its average volume of 126812.
More news about CELYAD ONCOLOGY.
4. SATS (SATS.OL)
8.41% Price Change
Sats ASA provides fitness and training services in Norway, Sweden, Denmark, and Finland. The company offers sportswear, fitness gear, bars, and energy drinks. It operates 262 fitness clubs under the SATS, ELIXIA, Fresh Fitness, HiYoga, and Mentra brands. The company was founded in 1995 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with SATS jumping 8.41% to €6.83 on Monday while Oslo Børs Benchmark Index_GI jumped 1.07% to €1,165.34.
Earnings Per Share
As for profitability, SATS has a trailing twelve months EPS of kr-2.63.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.63%.
Volatility
SATS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.15%, a negative 1.70%, and a positive 2.22%.
SATS’s highest amplitude of average volatility was 5.15% (last week), 2.38% (last month), and 2.22% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 3.2% and a drop 266.7% for the next.
More news about SATS.
5. MAJOREL GROUP LUX (MAJ.AS)
6.22% Price Change
Majorel Group Luxembourg S.A. engages in the designing, building, and delivering end-to-end customer experience (CX) solutions for digital-native and vertical leading brands worldwide. It offers customer interaction services, such as solutions for customer services, sales and marketing, loyalty and retention, and tech support; business process services, including content services, trust and safety, and vertical business process outsourcing services; and tech and expert services comprising digital consumer engagement, CX consulting, start-ups, and vertical digital solutions. The company serves Internet, banking and financial services, insurance, automotive, consumer products and retail, travel and hospitality, utilities and energy, and telecoms and media industries. Majorel Group Luxembourg S.A. was incorporated in 2018 and is headquartered in Luxembourg City, Luxembourg.
AEX-Index ended the session with MAJOREL GROUP LUX jumping 6.22% to €19.14 on Monday, after five sequential sessions in a row of losses. AEX-Index rose 0.92% to €729.05, following the last session’s downward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, MAJOREL GROUP LUX has a trailing twelve months EPS of €373.76.
PE Ratio
MAJOREL GROUP LUX has a trailing twelve months price to earnings ratio of 0.05. Meaning, the purchaser of the share is investing €0.05 for every euro of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MAJOREL GROUP LUX’s stock is considered to be overbought (>=80).
Volatility
MAJOREL GROUP LUX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.83%, a negative 1.55%, and a positive 1.67%.
MAJOREL GROUP LUX’s highest amplitude of average volatility was 4.83% (last week), 2.04% (last month), and 1.67% (last quarter).
Volume
Today’s last reported volume for MAJOREL GROUP LUX is 80333 which is 481.61% above its average volume of 13812.
More news about MAJOREL GROUP LUX.
6. OSE IMMUNO (OSE.PA)
5.68% Price Change
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
CAC 40 ended the session with OSE IMMUNO jumping 5.68% to €5.20 on Monday while CAC 40 jumped 1.27% to €7,013.14.
Earnings Per Share
As for profitability, OSE IMMUNO has a trailing twelve months EPS of €-0.39.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.81%.
Volume
Today’s last reported volume for OSE IMMUNO is 24288 which is 8.06% above its average volume of 22475.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, OSE IMMUNO’s stock is considered to be overbought (>=80).
Moving Average
OSE IMMUNO’s worth is way under its 50-day moving average of €5.99 and way below its 200-day moving average of €6.40.
More news about OSE IMMUNO.
7. ITERA (ITERA.OL)
4.56% Price Change
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with ITERA rising 4.56% to €12.60 on Monday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 1.07% to €1,165.34, after five sequential sessions in a row of losses, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.48.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 26.25. Meaning, the purchaser of the share is investing kr26.25 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 138.07%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Oct 27, 2022, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 1.49%.
More news about ITERA.
8. ACTEOS (EOS.PA)
4.55% Price Change
ACTEOS S.A. designs, develops, integrates, and provides software and related services in the field of supply chain management in France, Germany, Lebanon, and internationally. It offers Acteos suite, which include forecasting and procurement system for point of sales/e-business/distribution centers; transportation management system to organize and manage transport activities; and warehouse management system, a modular solution to manage customers' warehouses. The company also provides software as a service, hotline, technical project management, and consulting services. ACTEOS S.A. was founded in 1986 and is headquartered in Roubaix, France.
CAC 40 ended the session with ACTEOS jumping 4.55% to €1.73 on Monday while CAC 40 jumped 1.27% to €7,013.14.
Earnings Per Share
As for profitability, ACTEOS has a trailing twelve months EPS of €0.04.
PE Ratio
ACTEOS has a trailing twelve months price to earnings ratio of 43.12. Meaning, the purchaser of the share is investing €43.12 for every euro of annual earnings.
Moving Average
ACTEOS’s worth is above its 50-day moving average of €1.67 and above its 200-day moving average of €1.61.
Volatility
ACTEOS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.61%, a positive 0.01%, and a positive 2.64%.
ACTEOS’s highest amplitude of average volatility was 2.43% (last week), 3.00% (last month), and 2.64% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.7%, now sitting on 14.2M for the twelve trailing months.
More news about ACTEOS.
9. ONWARD MEDICAL (ONWD.BR)
4.55% Price Change
Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARCEX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer, which restores or enhances physical movement of hand and arm function to people with spinal cord therapy; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord that enables long-paralyzed people to stand and walk again with little or no assistance. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of ARCEX Therapy in restoring strength and function of upper extremities in people with spinal cord injury. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
BEL 20 ended the session with ONWARD MEDICAL rising 4.55% to €4.60 on Monday, following the last session’s downward trend. BEL 20 jumped 0.78% to €3,630.99, following the last session’s downward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-2.556.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -289.49%.
Moving Average
ONWARD MEDICAL’s value is way under its 50-day moving average of €5.35 and way under its 200-day moving average of €5.59.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONWARD MEDICAL’s stock is considered to be overbought (>=80).
Volatility
ONWARD MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.10%, a negative 1.07%, and a positive 2.09%.
ONWARD MEDICAL’s highest amplitude of average volatility was 5.23% (last week), 2.24% (last month), and 2.09% (last quarter).
More news about ONWARD MEDICAL.
10. OKEA (OKEA.OL)
4.5% Price Change
OKEA ASA, an oil and gas company, engages in the development and production of oil and gas in the Norwegian continental shelf. It holds 44.56% interests in Draugen, 12% interests in Gjøa, 2.77% interests in Ivar Aasen, and 15% interests in Yme assets. The company was incorporated in 2015 and is headquartered in Trondheim, Norway.
Oslo Børs Benchmark Index_GI ended the session with OKEA jumping 4.5% to €27.85 on Monday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 1.07% to €1,165.34, after five successive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, OKEA has a trailing twelve months EPS of kr-5.89.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.37%.
More news about OKEA.
Losers Today
1. NYRSTAR (NYR.BR)
-13.21% Price Change
Nyrstar NV does not have significant operations. Previously, it was engaged in the mining, smelting, and producing of zinc, lead, and other base and precious metals primarily in Europe, Australia, Canada, and the United States. Nyrstar NV was founded in 2007 and is based in Balen, Belgium.
BEL 20 ended the session with NYRSTAR dropping 13.21% to €0.12 on Monday while BEL 20 jumped 0.78% to €3,630.99.
Earnings Per Share
As for profitability, NYRSTAR has a trailing twelve months EPS of €-7.066.
Volatility
NYRSTAR’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.65%, a positive 0.18%, and a positive 2.68%.
NYRSTAR’s highest amplitude of average volatility was 2.65% (last week), 4.16% (last month), and 2.68% (last quarter).
Moving Average
NYRSTAR’s value is way below its 50-day moving average of €0.15 and way under its 200-day moving average of €0.19.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NYRSTAR’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
NYRSTAR’s stock is valued at €0.12 at 21:40 EST, way under its 52-week high of €0.29 and higher than its 52-week low of €0.11.
More news about NYRSTAR.
2. GROUPE JAJ (GJAJ.PA)
-11.95% Price Change
Groupe JAJ distributes clothing, shoes, and accessories. The company was formerly known as JAJ Distribution and changed its name to Groupe JAJ. Groupe JAJ is based in Montreuil, France.
CAC 40 ended the session with GROUPE JAJ sliding 11.95% to €1.40 on Monday while CAC 40 rose 1.27% to €7,013.14.
Earnings Per Share
As for profitability, GROUPE JAJ has a trailing twelve months EPS of €-0.045.
Volatility
GROUPE JAJ’s last week, last month’s, and last quarter’s current intraday variation average was a positive 3.25%, a negative 0.01%, and a positive 5.33%.
GROUPE JAJ’s highest amplitude of average volatility was 3.25% (last week), 2.59% (last month), and 5.33% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GROUPE JAJ’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for GROUPE JAJ is 1500 which is 155.53% above its average volume of 587.
More news about GROUPE JAJ.
3. BALYO (BALYO.PA)
-11.57% Price Change
Balyo SA designs, develops, and markets material handling robots worldwide. The company offers robotic pallet and reach trucks, tuggers, stackers, counterbalanced stackers, very narrow aisles, and autonomous mobile robots. Its products are used in intelligent pallet detection, barcode scanning, inter-building transport, push button configuration, machine interface, ERP interfacing, and palletizers; and WMS interface and 3D camera applications. The company serves 3PL, automotive, e-commerce, and consumer goods industries. Balyo SA was founded in 2004 and is headquartered in Arcueil, France.
CAC 40 ended the session with BALYO falling 11.57% to €0.67 on Monday, after three sequential sessions in a row of losses. CAC 40 rose 1.27% to €7,013.14, following the last session’s downward trend on what was an all-around bullish trend trading session today.
Earnings Per Share
As for profitability, BALYO has a trailing twelve months EPS of €-0.18.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BALYO’s stock is considered to be overbought (>=80).
Volatility
BALYO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.90%, a positive 0.12%, and a positive 3.39%.
BALYO’s highest amplitude of average volatility was 4.90% (last week), 3.57% (last month), and 3.39% (last quarter).
Yearly Top and Bottom Value
BALYO’s stock is valued at €0.67 at 21:40 EST, way below its 52-week high of €1.26 and way above its 52-week low of €0.38.
More news about BALYO.
4. PIERRE VAC BSA ACT (VACBS.PA)
-10% Price Change
CAC 40 ended the session with PIERRE VAC BSA ACT dropping 10% to €0.22 on Monday, after consecutive sessions in a row of losses. CAC 40 jumped 1.27% to €7,013.14, following the last session’s downward trend on what was an all-around positive trend exchanging session today.
Yearly Top and Bottom Value
PIERRE VAC BSA ACT’s stock is valued at €0.22 at 21:40 EST, below its 52-week low of €0.24.
More news about PIERRE VAC BSA ACT.
5. XILAM ANIMATION (XIL.PA)
-8.57% Price Change
Xilam Animation operates as an audiovisual production company in France and internationally. The company creates, produces, and distributes original programs for children and adults. It also broadcasts content on television; subscription video on demand streaming platforms, including Netflix, Disney +, Amazon, and NBC Universal; and advertising video on demand streaming platforms, such as YouTube, Facebook, Rakuten TV, Tubi, and Pluto TV. In addition, the company produces animated, short, and feature films. It owns the Oggy, Cockroaches, Zig & Sharko, Chicky, Oggy Oggy, Oggy Next Gen, Les Contes de Lupin, Moka, Mr Magoo, Trico, and J'ai Perdu Mon Corps brands. The company was incorporated in 1999 and is headquartered in Paris, France.
CAC 40 ended the session with XILAM ANIMATION sliding 8.57% to €24.00 on Monday while CAC 40 jumped 1.27% to €7,013.14.
Earnings Per Share
As for profitability, XILAM ANIMATION has a trailing twelve months EPS of €1.27.
PE Ratio
XILAM ANIMATION has a trailing twelve months price to earnings ratio of 18.93. Meaning, the purchaser of the share is investing €18.93 for every euro of annual earnings.
More news about XILAM ANIMATION.
6. GENOMIC VISION (GV.PA)
-8.18% Price Change
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company offers FiberVision, a molecular combing platform that helps in DNA analysis workflow; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision, a scanner that acquires high resolution images of the whole surface of the coverslip with a hands-off workflow; FiberStudio, a software, which detects hybridization signals and analyzes data to generate results and reporting; FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. It also provides FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, the company offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. It has a strategic alliance with Quest Diagnostics; and development agreement with La Timone Hospital; research and development agreement with the Institut Pasteur. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.
CAC 40 ended the session with GENOMIC VISION sliding 8.18% to €0.02 on Monday, after five successive sessions in a row of losses. CAC 40 rose 1.27% to €7,013.14, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, GENOMIC VISION has a trailing twelve months EPS of €-0.119.
Volatility
GENOMIC VISION’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.58%, a positive 1.90%, and a positive 5.53%.
GENOMIC VISION’s highest amplitude of average volatility was 2.58% (last week), 8.41% (last month), and 5.53% (last quarter).
More news about GENOMIC VISION.
7. ADOCIA (ADOC.PA)
-7.86% Price Change
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.
CAC 40 ended the session with ADOCIA dropping 7.86% to €2.93 on Monday while CAC 40 rose 1.27% to €7,013.14.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-3.345.
Volume
Today’s last reported volume for ADOCIA is 51574 which is 78.47% above its average volume of 28897.
Yearly Top and Bottom Value
ADOCIA’s stock is valued at €2.93 at 21:40 EST, way under its 52-week high of €6.46 and above its 52-week low of €2.80.
More news about ADOCIA.
8. KAHOOT! (KAHOT.OL)
-7.55% Price Change
Kahoot! ASA operates a game-based learning platform in the United States, Canada, Europe, the Asia Pacific, the Latin America and the Caribbean, Africa, the Middle East, and India. The company's platforms help to create, share, and host learning sessions. It offers Kahoot! Learning platform for learning and engagement services; employee engagement and learning platforms, such as Actimo and Motimate; Drops, a language learning app for visuals and play; Kahoot! DragonBox app for math learning; and Kahoot! Poio Read app, which empowers children to learn to read through play. The company also provides Kahoot! Academy, a knowledge platform, online community, and marketplace, which allows educators and publishers to join and create learning communities, as well as provides parents and learners with access to learning content from the educators; Kahoot! 360 Spirit, a collaborative platform for organizations that seek to connect teams and individuals; Kahoot! EDU support program, a site license for schools and districts; and Whiteboard.fi, an online whiteboard that provides learning tools for educators, teachers, and classrooms. In addition, it offers Kahoot! Zoom App platform for engagement and learning to virtual meetings and events; and Clever, a single sign-on digital learning platform for teachers and students. The company has approximately 2 billion participating players in approximately 200 countries. Kahoot! ASA was founded in 2012 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with KAHOOT! falling 7.55% to €21.44 on Monday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 1.07% to €1,165.34, after five successive sessions in a row of losses, on what was an all-around bullish trend trading session today.
Earnings Per Share
As for profitability, KAHOOT! has a trailing twelve months EPS of kr-0.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.38%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 266.7% and 120%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
KAHOOT!’s EBITDA is -2.53.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, KAHOOT!’s stock is considered to be oversold (<=20).
More news about KAHOOT!.
9. ERYTECH PHARMA (ERYP.PA)
-7.01% Price Change
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
CAC 40 ended the session with ERYTECH PHARMA sliding 7.01% to €0.72 on Monday while CAC 40 rose 1.27% to €7,013.14.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-3.99.
More news about ERYTECH PHARMA.
10. FAURECIA (EO.PA)
-6.73% Price Change
Faurecia S.E., together with its subsidiaries, manufactures and sells automotive technology solutions in France, Germany, other European countries, the Americas, Asia, and internationally. It operates through Seating, Interiors, Clean Mobility, Electronics, Lighting, and Lifecycle Solutions segments. The Seating segment designs and manufactures vehicle seats, seating frames, covers, and comfort solutions, as well as adjustment mechanisms. The Interior segment designs, manufactures, and assembles instrument panels, cockpits, and door panels and modules, as well as center consoles, and sustainable materials. The Clean Mobility segment designs and manufactures exhaust system solutions for passenger and commercial vehicles; fuel cell electric vehicles; and aftertreatment solutions for commercial vehicles, as well as zero-emissions solutions. The Electronics segment designs and manufactures display technologies, driver assistance systems, and cockpit electronics, as well as sensors and actuators, lighting/body electronics, energy management, and HMI/displays. The Lighting segment designs and manufactures lighting technologies. The Lifecycle Solutions segment provides solutions extending the vehicle lifecycle, as well as workshop equipment and special original equipment. The company was incorporated in 1929 and is headquartered in Nanterre, France.
CAC 40 ended the session with FAURECIA falling 6.73% to €17.52 on Monday, after three successive sessions in a row of losses. CAC 40 rose 1.27% to €7,013.14, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, FAURECIA has a trailing twelve months EPS of €-2.75.
Volume
Today’s last reported volume for FAURECIA is 1437690 which is 2.86% above its average volume of 1397680.
More news about FAURECIA.
Stay up to date with our winners and losers daily report
